These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 15926761)

  • 21. Review article: tegaserod for chronic constipation.
    Johanson JF
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 7():20-4. PubMed ID: 15521851
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The economic burden of treatment failure amongst patients with irritable bowel syndrome with constipation or chronic constipation: a retrospective analysis of a Medicaid population.
    Guerin A; Carson RT; Lewis B; Yin D; Kaminsky M; Wu E
    J Med Econ; 2014 Aug; 17(8):577-86. PubMed ID: 24811855
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of withdrawing tegaserod treatment in comparison with continuous treatment in irritable bowel syndrome patients with abdominal pain/discomfort, bloating and constipation: a clinical study.
    Bardhan KD; Forbes A; Marsden CL; Mason T; Short G
    Aliment Pharmacol Ther; 2004 Jul; 20(2):213-22. PubMed ID: 15233702
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study.
    Paré P; Gray J; Lam S; Balshaw R; Khorasheh S; Barbeau M; Kelly S; McBurney CR
    Clin Ther; 2006 Oct; 28(10):1726-35; discussion 1710-1. PubMed ID: 17157129
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship of compliance with hormone replacement therapy to short-term healthcare utilization in a managed care population.
    Hurley JS; Frost EJ; Trinkaus KM; Buatti MC; Emmett KE
    Am J Manag Care; 1998 Dec; 4(12):1691-8. PubMed ID: 10339101
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The economic burden of lung cancer and the associated costs of treatment failure in the United States.
    Kutikova L; Bowman L; Chang S; Long SR; Obasaju C; Crown WH
    Lung Cancer; 2005 Nov; 50(2):143-54. PubMed ID: 16112249
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Costs of care for irritable bowel syndrome patients in a health maintenance organization.
    Levy RL; Von Korff M; Whitehead WE; Stang P; Saunders K; Jhingran P; Barghout V; Feld AD
    Am J Gastroenterol; 2001 Nov; 96(11):3122-9. PubMed ID: 11721759
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tegaserod for the treatment of constipation-predominant irritable bowel syndrome.
    Baker DE
    Rev Gastroenterol Disord; 2001; 1(4):187-98. PubMed ID: 12120185
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
    Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
    Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Societal costs for irritable bowel syndrome--a population based study.
    Hillilä MT; Färkkilä NJ; Färkkilä MA
    Scand J Gastroenterol; 2010 May; 45(5):582-91. PubMed ID: 20166844
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of tegaserod on recto-sigmoid tonic and phasic activity in constipation-predominant irritable bowel syndrome.
    Di Stefano M; Miceli E; Mazzocchi S; Tana P; Missanelli A; Corazza GR
    Am J Gastroenterol; 2007 Aug; 102(8):1720-6. PubMed ID: 17521397
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The budget impact of endoscopic screening for esophageal varices in cirrhosis.
    Spiegel BM; Esrailian E; Eisen G
    Gastrointest Endosc; 2007 Oct; 66(4):679-92. PubMed ID: 17905009
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A response to Farup and Bytzer. Tegaserod Nordic trial.
    Nyhlin H; Hunt R
    Scand J Gastroenterol; 2004 Aug; 39(8):803-4. PubMed ID: 15513374
    [No Abstract]   [Full Text] [Related]  

  • 34. Total costs of IBS: employer and managed care perspective.
    Cash B; Sullivan S; Barghout V
    Am J Manag Care; 2005 Apr; 11(1 Suppl):S7-16. PubMed ID: 15926759
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The FDA's decision-making process: isn't it time to temper the principle of protective paternalism?
    Brandt LJ
    Am J Gastroenterol; 2008 May; 103(5):1226-7. PubMed ID: 18477347
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Economic evaluation of tegaserod vs. placebo in the treatment of patients with irritable bowel syndrome: an analysis of the TENOR study.
    Bracco A; Jönsson B; Ricci JF; Drummond M; Nyhlin H
    Value Health; 2007; 10(4):238-46. PubMed ID: 17645678
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Healthcare utilization and costs of patients with rosacea in an insured population.
    Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
    J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Review article: the safety profile of tegaserod.
    Schoenfeld P
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 7():25-30. PubMed ID: 15521852
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Health care resource use associated with integrated psychological treatment.
    Vasiliadis HM; Briand C; Lesage A; Reinharz D; Stip E; Nicole L; Lalonde P
    J Ment Health Policy Econ; 2006 Dec; 9(4):201-7. PubMed ID: 17200597
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Utilization patterns and net direct medical cost to Medicaid of irritable bowel syndrome.
    Martin BC; Ganguly R; Pannicker S; Frech F; Barghout V
    Curr Med Res Opin; 2003; 19(8):771-80. PubMed ID: 14687449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.